И его применение при заболеваниях легких
жүктеу/скачать 142,06 Kb. Pdf көрінісі
|
1089-757-1-PB
Өкпенің ауамен
| Pison U., Seeger W., Buchhorn R. et al
. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am. Rev. Respir. Dis. 1989; 140: 1033—1039. 93. Green K. E., Wright J. R., Steinberg K. R. et al. Serial changes in surfac tantassociated proteins in lung and serum before and after onset of ARDS. Am. J. Resp. Crit. Care Med. 1999; 160: 843—1850. 94. Lewis J. F., Veldhuizen R., Possmayer F. et al. Altered alveolar surfactant is an early marker of acute lung injury in septic adult sheep. Am. J. Resp. Crit. Care Med. 1994; 150 (1): 123—130. 95. Veldhuizen R., McCaig L. A., Akino T. et al. Pulmonary surfactant sub fractions in patients with the acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1995; 152: 1867—1871. 96. Cockshutt A. M., Weitz J., Possmayer F. Pulmonary surfactantassociated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424—8429. 97. Fuchimukai T., Fujiwara T., Takahashi A. Artificial pulmonary surfactant inhibition by proteins. J. Appl. Physiol. 1987; 62: 429—437. 98. Seeger W., Stohr G., Wolf H. R. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 1985; 58: 326—338. 99. Holm B. A., Notter R. H. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J. Appl. Physiol. 1987; 63: 1434—1442. 100. Seeger W., Thede C., Gunter A. et al. Surface properties and sensitivity to proteininhibition of a recombinant apoprotein Cbased phospho lipids mixture in vitrocomparison to natural surfactant. Biochim. Biophys. Acta 1991; 1081: 45—52. 101. Seeger W., Gunther A., Thede C. Differential sensitivity to fibrinogen inhibition of SPC vs. SPBbased surfactants. Am. J. Physiol. 1992; 262: 286—291. 102. Venkitaraman A. R., Gunther A., Thede C. et al. Biophysical inhibition of synthetic phosphilipidlung surfactant apoprotein admixtures by plasma proteins. Chem. Phys. Lipids 1991; 57: 49—57. 103. Gunther A., Kalinovski M., Rosseau S. et al. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am. J. Respir. Cell Mol. Biol. 1995; 13: 712—718. 104. Seeger W., Elssner A., Gunter A. et al. Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am. J. Respir. Cell Mol. Biol. 1993; 9: 213—220. 105. Gunther A., Markart P., Kalinowski M. et al. Cleavage of surfactant incorporated fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Am. J. Respir. Cell Mol. Biol. 1999; 21: 738—745. 106. Schermuly R. T., Gunter A., Ermert M. et al. Conebulization of surfac tant and urokinase restores gas exchange in perfused lungs with alve olar fibrin formation. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280: 792—800. 107. Baker C. S., Evans T. W., Randle B. J. et al. Damage to surfactantspe cific protein in acute respiratory distress syndrome. Lancet 1999; 353: 1232—1235. 108. Pison U., Obertacke U., Brand M. et al. Altered pulmonary surfactant in uncomplicated and septicemiacomplicated courses of acute respi ratory failure. J. Trauma 1990; 30: 19—26. 109. Petty T. L., Silvers G. W., Paul G. et al. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syn drome. Chest 1979; 75: 571—574. 110. G ü nter A., Schmidt R., Harold J. at al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact of bio physical and biochemical surfactant properties. Eur. Respir. J. 2002; 19: 797—804. 111. Gregory T. J., Steinberg K. R., Spragg R. et al. Bovine surfactant thera py for patients with acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1997; 155: 1309—1315. 112. Hohlfeld J. M. Potential role of surfactant in asthma. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 44—45. 113. Kurashima K., Fuimura M., Matsuda T., Kobauashi T. Surface activity of sputum from acute asthmatic patients. Am. J. Respir. Crit. Care Med. 1997; 155: 1254—1257. 114. Cheng G. et al. Compositional and functional changes of pulmonary surfactant in a guineapig model of chronic asthma. Respir. Med. 2001; 95: 180—186. 115. Liu M., Wang L., Enhorning G. Surfactant dysfunction develops when the immunized guineapig is challenged with ovalbumin aerosol. Clin. Exp. Allergy 1995; 25: 1053—1056. 116. Morley C. J. et al . Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 1: 64—66. 117. Revak S. D., Merritt T. A., Hallman M. et al. The use of synthetic pep tides in the formation of biophysically and biologically active pul monary surfactants Pediatr. Res. 1991; 29: 460465. 118. H ä fner D., Germann P. =G., Hauschke D. Effects of rSPC surfactant on oxygenation and histology in a ratlunglavage model of acute lung injury. Am. J. Respir. Crit. Care Med. 1998; 158: 270—276. 119. Баутин А. Е., Осовских В. В., Хубулава Г. Г. и др. Многоцентровые клинические испытания сурфактантаBL для лечения респира торного дистресссиндрома взрослых. Клинические исследова ния лекарственных средств в России 2002; (2): 18—23. 120. Curstedt T., Jornvall H., Berggren P. et al. Artificial surfactant based on different hydrophobic lowmolecular — weight proteins. In: Lachmann B. (ed.) Surfactant replacement therapy in neonatal and adult respira tory distress syndrome. Berlin: SpringerVerlag; 1988. 332—337. 121. Hallman M. , Meritt T. A., Schneider H. et al. Isolation of human sur factant from amniotic fluid and pilot study of its efficacy in respirato ry distress syndrome. Pediatrics 1983; 71: 473—482. О Б Щ А Я Р Е А Н И М А Т О Л О Г И Я , 2 0 0 7 , I I I ; 1 76 жүктеу/скачать 142,06 Kb. Достарыңызбен бөлісу:
|